According to FutureWise analysis the market for headache disorders in 2023 is US$ 4.25 billion, and is expected to reach US$ 7.1 billion by 2031 at a CAGR of 6.62%.
Headache disorders, which are characterised by frequent headaches, are the most common nervous system disorders. Tension-type headache, migraine, cluster headache, are some of the serious headache and disabling symptoms. Overuse of medications is another common cause of headaches. The numerous pharmaceuticals used to treat headache disorders include antipsychotic medications, calcium channel blockers, antiseizure medications, antidepressants, and nonsteroidal anti-inflammatory drugs (NSAIDs). Over half of the adult population is thought to have had a headache at least once in the year. Recurrent headache disorders have been linked to personal and social expenses of pain, disability, reduced quality of life, and financial costs. Only a small fraction of people with headaches are accurately diagnosed by a professional. Around the world, headache is unappreciated, underdiagnosed, and undertreated. An increase in the number of people suffering from depression, Increased investment in healthcare facilities, as well as an increase in migraine prevalence. The QULIPTATM (atogepant), the first and only oral CGRP receptor antagonist, was launched in September 2021. It was created exclusively for the prevention of migraine. CGRP and its receptors are utilised in the neurological system to help with migraine aetiology, and studies have shown that CGRP levels are higher during migraine attacks. QULIPTA is a CGRP-blocking medicine that is taken once a day. It is available in three different strengths: 10 mg, 30 mg, and 60 mg.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Headache Disorders Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Headache Disorders Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.